Yeast-based therapeutic for chronic hepatitis C infection

Details Yeast-based therapeutic for chronic hepatitis C infection Yeast-based therapeutic for chronic hepatitis C infection

2006-12-31

2009-12-15

Lucas, Zachariah (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S192100, C424S278100, C424S093100, C424S093510, C435S069300, C435S069700, C435S254110, C435S255100

Reexamination Certificate

active

07632511

ABSTRACT:
Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.

REFERENCES:
patent: 4775622 (1988-10-01), Hitzeman et al.
patent: 5413914 (1995-05-01), Franzusoff
patent: 5585258 (1996-12-01), Houghton et al.
patent: 5641654 (1997-06-01), Maki et al.
patent: 5683864 (1997-11-01), Houghton et al.
patent: 5830463 (1998-11-01), Duke et al.
patent: 5858378 (1999-01-01), Bostwick
patent: 5871903 (1999-02-01), Miyamura et al.
patent: 5919651 (1999-07-01), Hitzeman et al.
patent: 5930463 (1999-07-01), Park
patent: 5961978 (1999-10-01), Gaudernack et al.
patent: 6027729 (2000-02-01), Houghton et al.
patent: 6071693 (2000-06-01), Cha et al.
patent: 6074816 (2000-06-01), Houghton et al.
patent: 6090546 (2000-07-01), Breivik et al.
patent: 6121020 (2000-09-01), Selby et al.
patent: 6187307 (2001-02-01), Cohen
patent: 6194140 (2001-02-01), Houghton et al.
patent: 6284249 (2001-09-01), Barban
patent: 6326171 (2001-12-01), Selby et al.
patent: 6361969 (2002-03-01), Galeotti
patent: 6521423 (2003-02-01), Houghton et al.
patent: 6558951 (2003-05-01), Tomai et al.
patent: 6562346 (2003-05-01), Paliard et al.
patent: 6613333 (2003-09-01), Leroux-Roels et al.
patent: 6759046 (2004-07-01), Gaudernack et al.
patent: 6861057 (2005-03-01), Gaudernack et al.
patent: 6890737 (2005-05-01), Maertens et al.
patent: 6986892 (2006-01-01), Coit et al.
patent: 6989892 (2006-01-01), White
patent: 7048930 (2006-05-01), Bosman et al.
patent: 7052696 (2006-05-01), Fields et al.
patent: 7078416 (2006-07-01), Gaudernack et al.
patent: 7083787 (2006-08-01), Duke et al.
patent: 7192927 (2007-03-01), Gaudernack et al.
patent: 7563447 (2009-07-01), Franzusoff et al.
patent: 7595060 (2009-09-01), Duke et al.
patent: 2002/0004048 (2002-01-01), Ralston et al.
patent: 2002/0169125 (2002-11-01), Leung et al.
patent: 2003/0035810 (2003-02-01), Caplan
patent: 2003/0064499 (2003-04-01), Houghton et al.
patent: 2003/0108561 (2003-06-01), Bosman et al.
patent: 2003/0129586 (2003-07-01), Houghton et al.
patent: 2003/0152940 (2003-08-01), Sablon et al.
patent: 2004/0009937 (2004-01-01), Chen et al.
patent: 2004/0126395 (2004-07-01), Maertens et al.
patent: 2004/0138204 (2004-07-01), Harrington, Jr.
patent: 2004/0151735 (2004-08-01), Maertens et al.
patent: 2004/0156858 (2004-08-01), Franzusoff et al.
patent: 2005/0013828 (2005-01-01), George et al.
patent: 2005/0074465 (2005-04-01), Houghton
patent: 2006/0110755 (2006-05-01), Duke et al.
patent: 2008/0069831 (2008-03-01), Duke et al.
patent: 2009/0074805 (2009-03-01), Duke et al.
patent: 2009/0098154 (2009-04-01), Franzusoff et al.
patent: 2009/0142366 (2009-06-01), Franzusoff et al.
patent: 2009/0142367 (2009-06-01), Franzusoff et al.
patent: 2486400 (1982-01-01), None
patent: WO 9222571 (1992-12-01), None
patent: WO 9317110 (1993-09-01), None
patent: WO 02/39951 (2002-05-01), None
patent: WO 2004/005473 (2004-01-01), None
patent: WO 2004/046175 (2004-06-01), None
patent: WO 2004/046176 (2004-06-01), None
patent: WO 2004/058157 (2004-07-01), None
Han et al., “Identification of the protease domain in NS3 of hepatitis C virus,” Journal of General Virology, vol. 76 No. 4, pp. 985-993 (Apr. 1995).
Hitomi et al., “High efficiiency prokaryotic expression and purification of a portion of Hepatitis C Core Protein and analysis of the immune response to recombinant protein in BALB/c mice,” Viral Immunology, vol. 8 No. 2, pp. 109-119 (1995).
Di Bisceglie et al., Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon, Hepatology, vol. 33 No. 3, pp. 704-707 (Mar. 2001).
Bachmann et al., 1994, Curr. Op. Immunol., 6:320-326.
Bourdette et al., 1994, J. Immunol., 152:2510-2519.
Brossier et al., 1999, Infection and Immunity, 67(2): 964-967.
Brown, D., 1995, The Washington Post, “Gene Therapy ‘Oversold’ by Researchers, Journalists”.
Chou et al., 1994, J. Immunol., 152:2520-2529.
Coghlan, 1995, New Scientists, 145:14-15.
Cohen, 1994, Science, 264:1660.
Cohen, 1994, Science, 264:1839.
Engelhardt et al., 1994, Hum. Gene Ther, 5:1217-1229.
Franzusoff et al., 1995, J. Biol. Chem., 270(7):3154-3159.
Garber et al., 2003, AIDS Reviews, 5(3):131-139.
Gnirke et al., 1991, EMBO J., 10(7):1629-1634.
Hatsuyama et al., 1994, Plant Cell Physiol., 35(1):93-98.
Kaur et al., 2003, Topics in HIV Medicine, 11(3): 76-85.
Ketner et al., 1994, Proc. Natl. Acad. Sci. USA, 91:6186-6190.
Lechmann and Liang (2000) Semin Liver Dis. 20(2): 211-26.
Marshall, 1995, Science 269:1050-1055.
Moulard et al., 1994, Eur. J. Biochem. 225:565-572.
Mullen et al., 1994, Plant Physiol., 105:113 (Abstr. 606).
Mulligan, 1993, Science, 260:926-931.
Peterson et al., 1993, Proc. Natl. Acad. Sci. USA, 90:11207-11211.
Sanchez-Pescador et al., 1985, Science, 227:484-492.
Stern et al., 1992, Cell, 68:465-477.
Suda et al., 1993, Cell, 75:1169-1178.
GENPEPT AAB67036, “polyprotein [Hepatitis C virus strain H77]”, Aug. 16, 1997.
Park et al., “Monitoring antibody titers to recombinant Core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy.” Journal of Korean medical science, Apr. 1999, vol. 14, No. 2, pp. 165-170.
Seong et al., “Overexpression and simple purification of a truncated immunologically reative GST-HCV core (1-123) fusion protein”, Journal of Virological Methods, May 1996, vol. 59, Nos. 1-2, pp. 13-21.
International Search Report for International (PCT) Patent Application No. PCT/US05/37499, mailed Jan. 11, 2008.
Written Opinion for International (PCT) Patent Application No. PCT/US05/37499, mailed Jan. 11, 2008.
Adams et al. International Reviews of Immunology, vol. 11 No. 2, pp. 133-141 (1994).
Allsopp et al., European Journal of Immunology, vol. 26 No. 8, pp. 1951-1959 (1996).
Acosta-Rivero et al., 2002, Biochemical and Biophysical Research Com., 295: 81-84.
Baker et al., 1988, Cell, 54:335-344.
Bizzini et al., 1990, FEMS Microbiol. Immunol., 64:155-168.
Brake et al., 1984, Proc. Natl. Acad. Sci. USA, 81:4642-4646.
Chien et al., 1992, Proc. Natl. Acad Sci. USA., 89:10011-10015.
Khu et al., 2004, Biochem. J., 384:401-409.
Martinez-Donato et al., 2006, Biochemical and Biophysical Research Comm., 342:625-631.
Markland et al., 1997, Journal of General Virology., 78:39-43.
Mustilli et al., 1999, Res. Microbiol., 150:179-187.
Parolin et al., 2005, Journal of Biotechnology, 120:45-58.
Davies et al., 1992, Nucleic Acids Res., 20(11):2693-2698.
Demmer et al., 1993, J. Immunol., 150(12):5371-5378.
Rosa et al., 1996, Proc. Natl. Acad. Sci. USA, 93:1759-1763.
Fattal-German et al., 1992, Develop. Biol. Standard., 77:115-120.
Gobin et al., 1995, Gene, 163:27-33.
Fujita et al., 1987, Bulletin of the World Health Organization, 65(3):303-308.
Layton et al. Immunology, vol. 87 No. 2, pp. 171-178 (1996).
Markie et al., 1993, Somat. Cell Mol. Genet., 19(2):161-169.
Moore et al., 1996, FASEB J., 10(6) Abstract 2725.
Pachnis et al., 1990, Proc. Natl. Acad. Sci. USA, 87:5109-5113.
Paglia et al., Journal of Experimental Medicine, vol. 183 No. 1, pp. 317-322 (1996).
Rabinovich et al., 1994, Science, 265:1401-1404.
Schreuder et al., 1996 Vaccine, 14(5):383-388.
Sousa et al., Journal of Experimental Medicine, vol. 178 No. 2, pp. 509-519 (Aug. 1993).
O'Brien et al. (2000) Protein Sci. 9: 570-579.
Valenzuela et al., 1985 Bio/Technology 3:323-326.
Matsui et al. (2002) Vaccine. 21: 211-220.
Schupper et al., 1993, Hepatology, 18(5):1055-1060.
Vajdy, et al., “Hepatitis C virus polyprotein vaccine formulations capable of inducin

Affiliated with

Also associated with

Rating

Yeast-based therapeutic for chronic hepatitis C infection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Yeast-based therapeutic for chronic hepatitis C infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Yeast-based therapeutic for chronic hepatitis C infection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4141736